Physician profile
Edwin A Torres
NPI 1053715243
$76,288.71
in general payments reported to CMS, 2019-2025
20 companies · $17K in 2025
The $17K reported for 2025 was more than what 98% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,133 · 2022: $26K · 2023: $8,493 · 2024: $19K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $5,601 · Travel and Lodging: $5,318 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,150.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,400.00 |
| Food and Beverage | $5,600.81 |
| Travel and Lodging | $5,317.71 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32,042.42 | 2021-2025 | Ozempic, Victoza, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,771.26 | 2021-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $9,818.80 | 2021-2025 | |
| Lilly USA, LLC | $5,922.86 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $1,424.87 | 2021-2025 | Korlym |
| Esperion Therapeutics, INC. | $588.50 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $493.29 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $472.65 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $421.18 | 2021-2025 | Farxiga, Wainua |
| Xeris Pharmaceuticals, INC. | $282.67 | 2024-2025 | Recorlev |
| Abbott Laboratories | $252.95 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $208.02 | 2022 | |
| Amgen INC. | $157.67 | 2021-2023 | Repatha |
| Gilead Sciences, INC. | $126.86 | 2024 | |
| Amarin Pharma, INC. | $111.68 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $83.38 | 2022 | |
| Merck Sharp & Dohme LLC | $47.54 | 2021-2025 | Verquvo |
| Daiichi Sankyo INC. | $27.22 | 2023 | Injectafer |
| Insulet Corporation | $21.87 | 2025 | Omnipod |
| Genzyme Corporation | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.